为进一步提高我国乙型肝炎临床科研水平而努力  

Pursue excellence of clinical research on chronic hepatitis B in China

作　　者：贾继东[1] 

机构地区：[1]首都医科大学附属北京友谊医院肝病中心,北京100050

出　　处：《临床肝胆病杂志》2015年第4期481-482,共2页Journal of Clinical Hepatology

摘　　要：新生儿乙型肝炎疫苗普种使我国的HBsAg流行率由1992年的9．75％降低至2006年的7．18％。但现有慢性HBV感染者仍然高达9000万，其中慢性乙型肝炎患者2000万～3000万。干扰素类及核苷和核苷酸类药物可有效抑制HBV复制、延缓疾病进展，但难以彻底治愈乙型肝炎。积极研发针对HBV复制过程特异靶点的直接抗病毒药物以及针对其免疫应答关键环节的免疫疗法，是实现乙型肝炎治愈目标的技术关键。中国学者在优化现有乙型肝炎治疗方案、探索新疗法等方面开展了卓有成效的工作。采用公共卫生策略来提高乙型肝炎预防和治疗的可及性和可负担性、扩大预防接种和规范化治疗的覆盖人群是降低乙型肝炎相关疾病负担和社会经济负担的最有效手段。In China universal vaccination program against hepatitis B virus （HBV）in newborns has led to a dramatic decline in HBsAg prevalence from 9.75%in 1992 to 7.18%in 2006.However,it is estimated that there are still around 90 million patients with chronic HBV infection,including 20-30 million with chronic hepatitis B （CHB）.As recommended therapies,interferons and nucleos（t）ide analogues can effectively suppress HBV replication and thereby halt the progression of liver disease.Unfortunately,the current standard of care could not cure CHB in most cases.Developing direct antiviral agents targeting the specific steps of HBV life cycle or immunotherapy against the key steps of immune response to HBV infection will ultimately enable us to cure CHB.Chinese hepatologists have published more and more papers on HBV prevention and management,with the aim of optimizing current modalities and exploring new therapies.Adopting the public health policy to improve the accessibility and affordability of preventive and therapeutic drugs and increase the coverage of vaccination and standardized treatment is the most effective means to reduce the enormous health and socioeconomic burden of HBV-related diseases.

关 键 词：肝炎 乙型 综合预防 公共卫生 述评 

分 类 号：R512.62[医药卫生—内科学]